Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.
Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal
Camurus announced that the leading drug dependence journal Addiction published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal (prolonged-release buprenorphine), the first long-acting injection medicine to be approved for the treatment of opioid dependence in the EU and Australia.
With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.
Five U.S. states filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids, including OxyContin.
White Paper: Safety Profile of the Analgesic Trezix™ Capsules, Containing the Mild Opioid Dihydrocodeine
Privately held pharmaceutical company Wraser Pharmaceuticals announced the publication of a White Paper addressing opioid safety.
The U.S. government filed a civil lawsuit accusing Rochester Drug-Cooperative Inc., a large opioid distributor, of failing to report thousands of suspicious orders for controlled substances as part of a years-long drive to bolster profit.
Allergan reported in early March 2019 that an experimental adjunctive treatment for major depressive disorder failed to hit endpoints in a late-stage trial, however, a new study suggests rapastinel can benefit patients going through opioid withdrawal.
The one-time billionaire founder of Insys Therapeutics Inc. and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.
Members of the wealthy Sackler family behind Purdue Pharma LP pushed the company to boost sales of OxyContin and other opioids even as questions emerged about the extent the drugmaker’s painkillers were being abused, Massachusetts’ attorney general alleged.
The former chief executive of Insys Therapeutics Inc. agreed to plead guilty to participating in a scheme to bribe doctors.